State of New Jersey Common Pension Fund D Reduces Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

State of New Jersey Common Pension Fund D trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 16.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,234 shares of the biopharmaceutical company's stock after selling 13,518 shares during the period. State of New Jersey Common Pension Fund D's holdings in TG Therapeutics were worth $2,084,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in TGTX. State Street Corp raised its holdings in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in TG Therapeutics by 0.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company's stock worth $27,708,000 after acquiring an additional 7,939 shares during the period. Principal Financial Group Inc. lifted its stake in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after acquiring an additional 270,286 shares during the period. Finally, Barclays PLC boosted its position in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after acquiring an additional 158,323 shares during the period. Institutional investors own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TGTX. The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. StockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. TD Cowen initiated coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 10.50% of the company's stock.

TG Therapeutics Stock Up 0.6 %

TG Therapeutics stock traded up $0.18 during midday trading on Wednesday, hitting $29.39. 664,572 shares of the company's stock were exchanged, compared to its average volume of 2,142,459. The company has a market cap of $4.57 billion, a PE ratio of -293.93 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $36.84. The firm has a 50-day moving average of $30.87 and a two-hundred day moving average of $27.96.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.